Overview

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Status:
RECRUITING

Trial end date:
2030-04-18

Target enrollment:

Participant gender:

Summary

International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

Phase:

PHASE3

Details

Lead Sponsor:

AstraZeneca

Treatments:

dapagliflozin